Aardvark Therapeutics, Inc.
AARD
$8.22
-$0.30-3.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 35.28% | -31.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 85.62% | 23.51% | |||
| Operating Income | -85.62% | -23.51% | |||
| Income Before Tax | -109.92% | -9.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -109.92% | -9.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -109.92% | -9.66% | |||
| EBIT | -85.62% | -23.51% | |||
| EBITDA | -85.56% | -- | |||
| EPS Basic | -106.00% | -9.14% | |||
| Normalized Basic EPS | -109.48% | -7.89% | |||
| EPS Diluted | -106.00% | -9.14% | |||
| Normalized Diluted EPS | -109.48% | -7.89% | |||
| Average Basic Shares Outstanding | 1.90% | 0.49% | |||
| Average Diluted Shares Outstanding | 1.90% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||